New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareChonluten vs Triptorelin

Chonluten vs Triptorelin

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Chonluten
Sexual Health & Libido
Triptorelin
Summary
Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) with 100x the potency of native GnRH. An FDA-approved drug (Trelstar) for prostate cancer and precocious puberty, it is also used in post-cycle therapy (PCT) to rapidly restart the hypothalamic-pituitary-gonadal (HPG) axis after anabolic steroid suppression.
Half-Life
Short (minutes for the peptide); sustained gene-regulatory effects
Depot forms: weeks to months; aqueous: 6-8 hours
Admin Route
SubQ, Oral
SubQ, IM
Research
Typical Dose
10 mg per day
100 mcg
Frequency
Daily for 10–30 days
Single injection
Key Benefits
  • Supports bronchial mucosal regeneration and repair
  • May improve mucociliary clearance in chronic respiratory conditions
  • Anti-inflammatory effects on bronchial epithelium
  • Pulmonary anti-aging and tissue preservation
  • Supports lung function in COPD and chronic bronchitis
  • Well tolerated in combination with other Khavinson bioregulators
  • Short tripeptide with efficient cellular penetration
  • Rapid HPG axis restart after steroid use
  • Single-injection PCT protocol possible
  • Massively elevates LH and FSH via flare effect
  • Restores endogenous testosterone faster than traditional PCT
  • FDA-approved for established medical uses
Side Effects
  • Generally well tolerated
  • Mild injection site reactions possible
  • No significant adverse pulmonary events reported
  • Initial testosterone flare (intended)
  • Injection site reactions
  • Hot flashes (with chronic use)
  • Decreased libido (chronic dosing)
Stacks With